Where Emerging FDA Draft Guidance may Lead for Nano-rare Patients
About this episode
The episode discusses the impact of emerging FDA draft guidance on drug development for nano-rare patients and the financial challenges faced in the process.
On This episode We Discuss: 2:30 – Andrew realized that finance plays a very large role in drug development and is an obstacle in for rare disease patients getting the treatments they need 4:30 – The triple whammy of drug development 6:22 – Economic decisions when lives are at stake; Balancing the ethical considerations of medicine and finance 12:17 – Small biotech companies are better for innovation, and a distributed investment process is more productive; Innovation comes from orthogonal thinking 22:40 – Very small prevalence disease drug programs tend to get terminated at commercial organizations; Movement toward finding a way to create a commercial path for extremely rare disease drugs 25:45 – FDA draft guidance for potential commercialization of nano-rare medicines; Where the guidance may lead; Value of a statistical life 30:32 – The cost of a nano-rare patient’s care; Courageous moves of the FDA 35:00 – Regulatory processes merging with the advances of science while still protecting patients Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at…
More episodes of Patient Empowerment Program: A Rare Disease Podcast
- Realizing Hope for Layken
- Realities of the Nano-rare: Episode 1 with Sarah Glass
- Miracles of Science #2: Induced Pluripotent Stem Cells
- Reflections from the n-Lorem Chairman | 2026
- Miracles of Science: Genomics
- Your Questions, Answered: 2026 Q&A
Explore listener stats, chart rankings, contacts and more on the Patient Empowerment Program: A Rare Disease Podcast podcast page.